Glenmark Pharmaceuticals enters oncology with GBR 1302

Glenmark's first clinical candidate targeting oncology indications

Glenmark Pharmaceuticals announced the its subsidiary Glenmark Pharmaceuticals S.A. (GPSA) has entered oncology with the discovery and initiation of IND enabling studies of a novel clinical development candidate, GBR 1302, a HER2xCD3 bispecific antibody.

GBR 1302 was discovered and developed by Glenmark Biologics Research Centre located in La Chaux-de-Fonds, Switzerland. GBR 1302 is based on Glenmark's innovative BEAT antibody technology platform.

Glenmark expects to obtain approval for the initiation of clinical studies during this financial year.

Powered by Capital Market - Live News